X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.prnewswire.com/news-releases/sciwind-biosciences-announces-positive-results-from-phase-1-clinical-trial-of-xw004-an-oral-formulation-of-long-acting-glp-1-analog-ecnoglutide-302042633.html
https://www.fiercebiotech.com/biotech/sciwind-blows-glp-1-contention-pivotal-data-chinese-rival-novo-lilly
https://www.prnewswire.com/news-releases/sciwind-biosciences-announces-publication-of-discovery-preclinical-and-phase-1-clinical-trial-results-of-ecnoglutide-xw003-in-molecular-metabolism-301873994.html
https://www.prnewswire.com/news-releases/sciwind-biosciences-announces-initiation-of-patient-dosing-in-phase-3-clinical-trials-of-ecnoglutide-xw003-a-long-acting-glp-1-analog-for-the-treatment-of-type-2-diabetes-in-china-301733145.html
https://www.prnewswire.com/news-releases/sciwind-biosciences-announces-positive-interim-results-from-ongoing-phase-2b-clinical-trial-of-xw003-ecnoglutide-in-patients-with-obesity-301660847.html
https://www.clinicaltrialsarena.com/news/sciwind-dosing-oral-drug-obesity/
https://www.prnewswire.com/news-releases/sciwind-biosciences-announces-initiation-of-dosing-in-phase-1-clinical-trial-evaluating-xw014-an-oral-small-molecule-glp-1-receptor-agonist-for-the-treatment-of-obesity-and-type-2-diabetes-301644252.html
https://www.prnewswire.com/news-releases/sciwind-biosciences-reports-positive-interim-results-from-phase-1c2a-clinical-trial-of-xw003-ecnoglutide-in-overweight-and-obese-adult-volunteers-in-china-301599771.html
https://www.prnewswire.com/news-releases/sciwind-biosciences-announces-positive-topline-results-from-20-week-phase-2-clinical-trial-of-xw003-ecnoglutide-a-novel-long-lasting-glp-1-analogue-in-adult-patients-with-type-2-diabetes-in-china-301597462.html
https://www.prnewswire.com/news-releases/sciwind-biosciences-to-present-data-from-its-glp-1-and-gip-receptor-agonist-programs-at-the-international-liver-congresstm-easl-2022-301562457.html
Market Place
Share 
